(MCRB) Seres Therapeutics - Ratings and Ratios
Microbiome, Therapeutics, Drugs, Infection, Recurrent
MCRB EPS (Earnings per Share)
MCRB Revenue
Description: MCRB Seres Therapeutics
Seres Therapeutics Inc (NASDAQ:MCRB) is a biotechnology company listed on the NASDAQ exchange, operating in the biotechnology sub-industry. The companys stock performance is characterized by high volatility, as indicated by its beta of 2.886, suggesting that its stock price movements are highly sensitive to market fluctuations.
From a financial perspective, Seres Therapeutics has a market capitalization of $124.09 million, with a forward price-to-earnings ratio of 8.12, indicating that the market expects the company to generate earnings in the future. The return on equity (RoE) of 283.91% suggests that the company is generating significant returns on shareholder equity, although this metric may be influenced by various factors, including accounting treatments and one-time events.
To evaluate the investment potential of MCRB, key performance indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and cash burn rate should be closely monitored. Additionally, key economic drivers, including the overall demand for biotechnology products, competition in the industry, and regulatory developments, will likely impact the companys financial performance. The companys ability to bring new products to market, achieve commercial success, and manage its cash resources effectively will be crucial in driving its stock performance.
From a trading perspective, MCRBs stock price has exhibited significant price movements, with a 52-week high of $23.20 and a low of $6.77. The stocks short-term and long-term moving averages (SMA20, SMA50, and SMA200) suggest that the stock has been trending upwards, although the high average true range (ATR) of 8.57% indicates that the stock price is subject to significant volatility.
MCRB Stock Overview
| Market Cap in USD | 171m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2015-06-26 |
MCRB Stock Ratings
| Growth Rating | -72.4% |
| Fundamental | 36.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -35.3% |
| Analyst Rating | 3.60 of 5 |
MCRB Dividends
Currently no dividends paidMCRB Growth Ratios
| Growth Correlation 3m | 92.2% |
| Growth Correlation 12m | -39.5% |
| Growth Correlation 5y | -94.6% |
| CAGR 5y | -51.11% |
| CAGR/Max DD 3y | -0.53 |
| CAGR/Mean DD 3y | -0.58 |
| Sharpe Ratio 12m | -0.60 |
| Alpha | -39.48 |
| Beta | 0.606 |
| Volatility | 173.64% |
| Current Volume | 151.7k |
| Average Volume 20d | 126.5k |
| Stop Loss | 14.5 (-7.6%) |
| Signal | -0.61 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (86.0m TTM) > 0 and > 6% of Revenue (6% = 357.5k TTM) |
| FCFTA -1.04 (>2.0%) and ΔFCFTA -64.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 297.8% (prev 11.0k%; Δ -10.7kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.42 (>3.0%) and CFO -59.9m <= Net Income 86.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (8.74m) change vs 12m ago 15.42% (target <= -2.0% for YES) |
| Gross Margin -50.54% (prev -2230 %; Δ 2180 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 2.56% (prev 0.12%; Δ 2.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -33.53
| (A) 0.12 = (Total Current Assets 48.7m - Total Current Liabilities 30.9m) / Total Assets 143.8m |
| (B) -6.71 = Retained Earnings (Balance) -965.3m / Total Assets 143.8m |
| warn (B) unusual magnitude: -6.71 — check mapping/units |
| (C) -0.49 = EBIT TTM -114.8m / Avg Total Assets 232.8m |
| (D) -8.71 = Book Value of Equity -965.3m / Total Liabilities 110.8m |
| Total Rating: -33.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.70
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -69.33% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 2.71 = -0.33 |
| 5. Debt/Ebitda -0.83 = -2.50 |
| 7. RoE 283.9% = 2.50 |
| 8. Rev. Trend -27.26% = -2.04 |
| 9. EPS Trend -48.43% = -2.42 |
What is the price of MCRB shares?
Over the past week, the price has changed by -31.33%, over one month by -5.99%, over three months by +109.20% and over the past year by -23.09%.
Is Seres Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MCRB is around 10.60 USD . This means that MCRB is currently overvalued and has a potential downside of -32.44%.
Is MCRB a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the MCRB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.3 | -15% |
| Analysts Target Price | 13.3 | -15% |
| ValueRay Target Price | 11.5 | -26.8% |
Last update: 2025-09-04 04:42
MCRB Fundamental Data Overview
CCE Cash And Equivalents = 45.4m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 10.8225
P/S = 390.2706
P/B = 5.1863
P/EG = -0.11
Beta = 2.886
Revenue TTM = 5.96m USD
EBIT TTM = -114.8m USD
EBITDA TTM = -108.2m USD
Long Term Debt = 79.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 9.48m USD (from shortTermDebt, last quarter)
Debt = 89.4m USD (Calculated: Short Term 9.48m + Long Term 79.9m)
Net Debt = 42.1m USD (from netDebt column, last quarter)
Enterprise Value = 214.9m USD (170.9m + Debt 89.4m - CCE 45.4m)
Interest Coverage Ratio = unknown (Ebit TTM -114.8m / Interest Expense TTM 0.0)
FCF Yield = -69.33% (FCF TTM -149.0m / Enterprise Value 214.9m)
FCF Margin = -2501 % (FCF TTM -149.0m / Revenue TTM 5.96m)
Net Margin = 1443 % (Net Income TTM 86.0m / Revenue TTM 5.96m)
Gross Margin = -50.54% ((Revenue TTM 5.96m - Cost of Revenue TTM 8.97m) / Revenue TTM)
Tobins Q-Ratio = -0.22 (set to none) (Enterprise Value 214.9m / Book Value Of Equity -965.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 89.4m)
Taxrate = 21.0% (US default)
NOPAT = -114.8m (EBIT -114.8m, no tax applied on loss)
Current Ratio = 1.57 (Total Current Assets 48.7m / Total Current Liabilities 30.9m)
Debt / Equity = 2.71 (Debt 89.4m / last Quarter total Stockholder Equity 33.0m)
Debt / EBITDA = -0.83 (Net Debt 42.1m / EBITDA -108.2m)
Debt / FCF = -0.60 (Debt 89.4m / FCF TTM -149.0m)
Total Stockholder Equity = 30.3m (last 4 quarters mean)
RoA = 59.78% (Net Income 86.0m, Total Assets 143.8m )
RoE = 283.9% (Net Income TTM 86.0m / Total Stockholder Equity 30.3m)
RoCE = -104.2% (set to none) (Ebit -114.8m / (Equity 30.3m + L.T.Debt 79.9m))
RoIC = -379.3% (set to none) (NOPAT -114.8m / Invested Capital 30.3m)
WACC = 5.42% (E(170.9m)/V(260.3m) * Re(8.25%)) + (D(89.4m)/V(260.3m) * Rd(0.0%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -12.12 | Cagr: -21.34%
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -149.0m)
EPS Correlation: -48.43 | EPS CAGR: -99.96% | SUE: -1.45 | # QB: False
Revenue Correlation: -27.26 | Revenue CAGR: -52.16%
Additional Sources for MCRB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle